Improvement in QoL and Reduction in LVP Requirement from the MOSAIC Study: A Multicenter, Open-Label, Prospective 3-Month Study of the Alfapump System in Refractory Ascites
AASLD LiverLearning®, Florence Wong, 195334
Combination Treatment of Tropifexor (LJN452) and Cenicriviroc Shows Additive Effects in a Diet-induced NASH Model
AASLD LiverLearning®, Eric Lefebvre, 195590
Hepato-cardiac Axis: Is It a Fact or a Myth?
AASLD LiverLearning®, Abdelfattah Hanno, 195335
A Liver-Targeted Acetyl-CoA Carboxylase Inhibitor Increases Fatty Acid Oxidation, Improves Mitochondrial Function and Reduces Bile Acids and Oxidative Stress in a Murine Model of NASH
AASLD LiverLearning®, Jamie Bates, 195591
The Clinical and Economic Toll Associated with Hepatorenal Syndrome from a Hospital Perspective in the United States: 2009-2015
AASLD LiverLearning®, Khurram Jamil, 195336
Methionine Aminopeptidase 2 Inhibition Attenuates Liver Pathology in Mouse Model of NASH
AASLD LiverLearning®, Bryan Burkey, 195592
Early Paracentesis Decreases All-Cause Mortality, But Not Mortality from Spontaneous Bacterial Peritonitis Between 2006-2014
AASLD LiverLearning®, Russell Rosenblatt, 195337
Whole-genome pooled CRISPR/Cas library screens to identify new hepatocellular carcinoma drivers and drug targets in conjunction with sorafenib
AASLD LiverLearning®, Takahiro Kodama, 195350
Single cell characterization of patatin-like phospholipase domain-containing protein 3 (PNPLA3) transcription pattern in human liver biopsies of nonalcoholic fatty liver disease
AASLD LiverLearning®, Bynvant Sandhu, 195606
MicroRNA-195 regulates chemoresistance via inhibition of epithelial-mesenchymal transition in human cholangiocarcinoma
AASLD LiverLearning®, Yu Ota, 195351
Development of A Novel Potent and Highly Selective PPAR a/d Dual Agonist (WXFL078) For the Treatment of NASH
AASLD LiverLearning®, Haiying He, 195607
Effect of CCL1 depletion on the antitumor defense in chimeras created with monocytes derived from patients with several stages of HCC
AASLD LiverLearning®, Akira Asai, 195352
Relaxin-2 Attenuates Hepatic Steatosis in Mice Fed a High-Fat or Methionine-Choline-Deficient Diet
AASLD LiverLearning®, Yun-Cheng Hsieh, 195608
Chemoprevention of Hepatocellular Carcinoma with Pioglitazone in a Rat Model of Cirrhosis.
AASLD LiverLearning®, Shen Li, 195366
ITIH4 as a Novel Biomarker of Hepatocellular Carcinoma Associated with Nonalcoholic Fatty Liver Diseases in a Newly Established Pig Model
AASLD LiverLearning®, Naohiko Namakura, 195622
MSI2 promotes liver fibrosis and hepatocarcinogenesis via activation of hepatic stellate cells
AASLD LiverLearning®, Jian Hong, 195367
Analysis of fibrogenic roles of liver infiltrating macrophages in a novel Non-alcoholic steatohepatitis (NASH) rat model with liver cirrhosis
AASLD LiverLearning®, Koichi Tsuneyama, 195623
Polyploidy and somatic copy number alterations in hepatocellular carcinoma
AASLD LiverLearning®, Sara Torrecilla, 195368
Functional roles of AGE-RAGE system for the development of hepatic fibrosis of NASH
AASLD LiverLearning®, Masafumi Ono, 195624
Pharmacological activator of NRF2, sulforaphane, inhibits hepatic cancer cell growth with attenuating angiogenesis
AASLD LiverLearning®, Shinya Sato, 195382
Cytotoxic CD8 T cells associated with ballooning and liver inflammation link Non-alcoholic Steatohepatitis with Type 2 diabetes mellitus.
AASLD LiverLearning®, Luisa Vonghia, 195638
miRNA-216 cluster in non-B and non-C hepatocellular carcinoma is related with disease-free survival
AASLD LiverLearning®, Takeshi Matsui, 195383
PRO-C3 in Combination With Clinical Parameters is Associated With Severity of Histological Features of Nonalcoholic Steatohepatitis and Fibrosis
AASLD LiverLearning®, Diana Leeming, 195639
Immunomodulation of aggressive liver cancer by EpCAM+ cancer stem cells through the activation of CCL20-CCR6 axis.
AASLD LiverLearning®, Mika Ohwada, 195384
Increase in Hepatocellular carcinoma (HCC) in patients with underlying Non-alcoholic fatty liver disease (NAFLD)
AASLD LiverLearning®, Sanath Allampati, 195640
miR-19a-3p regulates the expression of the PTEN via PI3K/Akt pathway in hepatocellular carcinoma
AASLD LiverLearning®, Ji-Min Zhu, 195398
HMGB1 inhibits hypoxia-induced ferroptosis in hepatocellular carcinoma cells
AASLD LiverLearning®, Wei Yan, 195399
Low Testosterone in Young Men Is Associated With Non-Alcoholic Fatty Liver Disease (NAFLD) in Midlife: Results from the Coronary Artery Risk Development in Young Adults (CARDIA) Study
AASLD LiverLearning®, Monika Sarkar, 195655
Impact of ARMC/ARMCX family genes in HCC development
AASLD LiverLearning®, Monica Higuera, 195400
Improvements in serum aminotransferase levels are associated with improvements in liver histology in children with nonalcoholic fatty liver disease (NAFLD)
AASLD LiverLearning®, Jeffrey Schwimmer, 195656
Age and gender-specific disease progression rates to cirrhosis and hepatocellular carcinoma (HCC) in treated and untreated patients with chronic hepatitis B
AASLD LiverLearning®, An Le, 195414
Evaluation of Cytochrome P450- and Transporter-Mediated Drug-Drug Interactions between the Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor Selonsertib and Phenotypic Probe Substrates or Prototypic Inhibitors/Inducers
AASLD LiverLearning®, Cara Nelson, 195670
Validation of the PAGE-B Model in Asian Chronic Hepatitis B Patients Receiving Entecavir or Tenofovir
AASLD LiverLearning®, Mi Na Kim, 195415
Specific activation of apoptosis inhibitor of macrophage (AIM) in patients with NASH-associated hepatocellular carcinoma
AASLD LiverLearning®, Tomoko Yamazaki, 195671
Cost-effectiveness of Screening for Hepatitis B Infection Prior to Solid Tumor Chemotherapy
AASLD LiverLearning®, Sirisha Grandhe, 195416
Cryptogenic Cirrhosis is not NASH Cirrhosis
AASLD LiverLearning®, Paul Thuluvath, 195672
Comparison of published noninvasive biomarkers to reliably exclude severe fibrosis in NAFLD patients.
AASLD LiverLearning®, Philip Newsome, 195685
Mortality among Adults with Chronic Hepatitis B Infection in the United States (US) from 1999 to 2010: Analysis of National Health and Nutrition Examination Surveys (NHANES) Data
AASLD LiverLearning®, Kali Zhou, 195430
Insulin secretion and decreased glucose clearance are associated with enhanced fibrogenesis and a high risk of disease progression in non-diabetic patients with Non Alcoholic Fatty Liver Disease
AASLD LiverLearning®, Chiara Rosso, 195686
Suboptimal rates, trends and predictors of hepatitis B vaccination in a population-based sample of children and adolescents in the United States (U.S.) between 1999 and 2014
AASLD LiverLearning®, Michael Le, 195431
Racial Disparities in the Relationship between Metabolic Syndrome Severity and the Risk of Mortality in Adults with Non-alcoholic Fatty Liver Disease
AASLD LiverLearning®, Mohamed Elsaid, 195687
HBV reactivation is rare in chronic hepatitis C patients with resolved HBV receiving direct acting antivirals: A systematic review and meta-analysis in cohort studies
AASLD LiverLearning®, Cheng Wang, 195432
Presumed Non-alcoholic Steatofibrosis Can Independently Predict Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)
AASLD LiverLearning®, Zobair Younossi, 195701
Serum Alanine Aminotransferase Level and Liver-related Mortality in Patients with Chronic Hepatitis B
AASLD LiverLearning®, Jae-Jun Shim, 195446
Light-to-Moderate Alcohol Consumption Protects Against Fatty Liver and Improves Insulin Resistance
AASLD LiverLearning®, Takemi Akahane, 195702
Rate and Predictors of Phase Transition Among North American Adults with HbeAg-Negative Chronic Hepatitis B and Low Level Viremia: a Hepatitis B Research Network (HBRN) Study
AASLD LiverLearning®, Kali Zhou, 195447
The Impact of Inadequate HCC Screening in patients with NASH Cirrhosis on Tumor Size
AASLD LiverLearning®, Elizabeth Aby, 195703
Prediction model of the progression of patients with acute deterioration of hepatitis B virus related chronic liver disease to acute-on-chronic liver failure
AASLD LiverLearning®, Chen Li, 195448
Trend In Prevalence and Incidence of Diagnosed Non Alcoholic Fatty Liver Disease (NAFLD)/Non Alcoholic Steatohepatitis (NASH) in the US, 2009 - 2014.
AASLD LiverLearning®, Vinod K. Rustgi, 195704
Could inherited predisposition drive fatty liver disease in non-obese Caucasians? Results from eight German tertiary referral centers
AASLD LiverLearning®, Marcin Krawczyk, 195717
Establishment and development of national demonstration areas to achieve control targets for hepatitis B in China
AASLD LiverLearning®, Bing Ruan, 195462
ZJU index independently predict the development of non-alcoholic fatty liver disease: a 7-year prospective study
AASLD LiverLearning®, Jinghua Wang, 195718
Validation of risk prediction models for the development of HBV-related HCC: a retrospective multi-center 10-year follow-up cohort study
AASLD LiverLearning®, Seung Up Kim, 195463
Hepatocellular injury and senescence in NASH are linked to Hedgehog and Hippo pathway activity and accumulation of hepatic progenitor cells
AASLD LiverLearning®, Cynthia Guy, 195719
The impact of treatment of chronic hepatitis B (CHB) on patient-reported outcomes (PROs)
AASLD LiverLearning®, Zobair Younossi, 195464
Subjects with Non-alcoholic Fatty Liver Disease and Severe Fibrosis Face a Significant Number of Adverse Events: Cryptogenic Cirrhosis and Severe Steatofibrosis
AASLD LiverLearning®, Zobair Younossi, 195720
Clinical significance of an ultra-high sensitive HBsAg assay to diagnosing HBV reactivation using stored samples of a prospective HBV DNA monitoring study in B-cell non-Hodgkin lymphoma patients
AASLD LiverLearning®, Shigeru Kusumoto, 195478
Renal tubular damage worsens over time in HBV monoinfected patients long-term treated with tenofovir: a prospective, single center, real-life study in 391 patients
AASLD LiverLearning®, Pietro Lampertico, 195479
High HBV Viral Load is associated with Mixed HBV Genotypes and Liver Stiffness in Co-infected HIV Mexican Patients
AASLD LiverLearning®, Arturo Panduro, 195480
NAFLD Patients with Metabolic Syndrome Have Significantly More Fat Deposition and Myosteatosis
AASLD LiverLearning®, Wei Zhang, 195736
Non-obese fatty liver disease is independently associated with lacunar infarct
AASLD LiverLearning®, Min-Sun Kwak, 195737
Diet/exercise programs are used by only one in five severely obese patients with biopsy-defined Nonalcoholic Fatty Liver Disease (NAFLD) advanced fibrosis in the Veterans Health Administration (VHA)
AASLD LiverLearning®, Yuval Patel, 195738
Genetic variants predict the histological severity of nonalcoholic fatty liver disease independent of insulin resistance
AASLD LiverLearning®, Sae Kyung Joo, 195739
A new method for the direct quantification of lipopolysaccharide by High Performance Liquid Chromatography coupled with Mass Spectrometry in non-infected cirrhotic patients (The MICROCIR cohort).
AASLD LiverLearning®, Delphine Weil, 195494
Liver Functional Assessment by Dual Cholate Testing Is Strongly Correlated with Direct Portal Pressure and Ishak Fibrosis Stage
AASLD LiverLearning®, Ohad Etzion, 195495
The Influence Of Transjugular Intrahepatic Portosystemic Shunt In The Need For Medical Care Of Cirrhotic Patients
AASLD LiverLearning®, José Ballester, 195496
Predictors of Fibrosis Progression and Regression by Histology and Morphometrically Quantified Collagen in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis
AASLD LiverLearning®, Zobair Younossi, 195752
Clinical Characteristics and Epidemiology of Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in a Large Community-based Healthcare Delivery System in the U.S.
AASLD LiverLearning®, Heather Patton, 195753
Progression to advanced liver disease in nonalcoholic fatty liver disease (NAFLD) differs among Asians compared to Caucasians and Hispanics
AASLD LiverLearning®, Nghiem Ha, 195754
Hepatic de novo lipogenesis is elevated in patients with NASH independent of disease severity
AASLD LiverLearning®, Eric Lawitz, 195755
Detailed Analyses of the Antifibrotic effects of INT-767, a dual FXR/TGR5 agonist, in an obese mouse model of diet-induced and biopsy-confirmed NASH
AASLD LiverLearning®, Sanne Veidal, 195510
miR-122 Inhibition in a Human Liver Spheroid Model Leads to Liver Inflammation, Necrosis, Steatofibrosis and Dysregulated Insulin Signaling
AASLD LiverLearning®, Hossein Sendi, 195511
Pharmacologic inhibition of FASN reverses diet-induced steatohepatitis in mice and inhibits lipogenesis in humans
AASLD LiverLearning®, Elizabeth Parks, 195512
Gut-dysbiosis due to reduced Clostridium subcluster XIVa is associated with the progression of nonalcoholic fatty liver disease: analysis based on the serum bile acid profile
AASLD LiverLearning®, Tadashi Ikegami, 195768
Differences in Clinical Characteristics between Eastern and Western Non-alcoholic Fatty Liver disease cohorts: A comparative study of 758 cases.
AASLD LiverLearning®, Mark Cheah, 195769
Understanding the Patient-Perceived Impact of Nonalcoholic Steatohepatitis: Raising the Volume on a Silent Disease
AASLD LiverLearning®, Maria-Magdalena Balp, 195770
Evaluation of the presence of steatosis and fibrosis in lipodystrophic with diabetes type 2 patients using transient elastography and comparison with antropometric and densitometric parameters
AASLD LiverLearning®, Melina Dias, 195771
Hepatocyte death-triggered CD11c-positive macrophage accumulation induces liver fibrosis in a murine model of non-alcoholic steatohepatitis
AASLD LiverLearning®, Michiko Itoh, 195526
Loss of miRNA-141/200c Cluster Ameliorates Hepatic Steatosis and Inflammation in Non-alcoholic Steatohepatitis
AASLD LiverLearning®, Melanie Tran, 195527
EDP-305 favorably regulates lipoprotein mechanism in vitro
AASLD LiverLearning®, Li-Juan Jiang, 195528
The secretin (SCT)/secretin receptor (SR) axis alters microRNA levels carried in extracellular vesicles that are responsible for cell-cell communication between cholangiocytes
AASLD LiverLearning®, Keisaku Sato, 195286
Comparative efficacy of obeticholic acid and INT-767 in the Gubra mouse NASH model of diet induced and biopsy-confirmed nonalcoholic steatohepatitis (NASH)
AASLD LiverLearning®, Jonathan Roth, 195542
Role of endothelial dysfunction in microRNA-34a knockout mice with cholestatic liver injury
AASLD LiverLearning®, Tianhao Zhou, 195287
Impact of PCSK7 genetic variation in patients with Non-Alcoholic Fatty Liver Disease
AASLD LiverLearning®, Paola Dongiovanni, 195543
YAP/β-catenin cross-talk promotes a pro-inflammatory phenotype in Fibrocystin-defective cholangiocytes
AASLD LiverLearning®, Luca Fabris, 195288
A novel long-acting FGF21 analogue significantly improves liver steatosis and halters progression of fibrosis in pre-clinical models of NASH
AASLD LiverLearning®, Emma Henriksson, 195544
An essential role of macrophages in cholangiocyte regeneration in a model of specific cholangiocyte injury
AASLD LiverLearning®, Adrien Guillot, 195289
NTCP inhibition has hepatoprotective effects in cholestasis by lowering bile salt load on hepatocytes and increasing the biliary phospholipid vs bile salt ratio
AASLD LiverLearning®, Reinout Roscam Abbing, 195302
The Dual Amylin and Calcitonin Receptor Agonist, KBP-089, Reduces Liver Steatosis, Inflammation and Fibrosis Stage in High Fat, High Cholesterol Fed Rats
AASLD LiverLearning®, Sofie Gydesen, 195558
Cenicriviroc, a cytokine receptor antagonist, potentiated the effects of all-trans retinoic acid by reducing neutrophils and T cells in the liver of rodent cholestatic models
AASLD LiverLearning®, Dongke Yu, 195303
Liver Rhythms and Bile Acid Metabolism in Mice Fed Chronic Alcohol + Binge
AASLD LiverLearning®, Jessica Ferrell, 195559
The thyromimetic GC-1 improves biliary injury but exacerbates hepatocyte injury in a mouse model of cholestasis
AASLD LiverLearning®, Kari Nejak-Bowen, 195304
The CD25 expression on CD4+ FoxP3- T cells in non-alcoholic fatty liver disease
AASLD LiverLearning®, Takuya Seike, 195560
Terlipressin Use, Transplant Rate, and Post-Transplant Outcomes in Patients With Type 1 Hepatorenal Syndrome (HRS)
AASLD LiverLearning®, Samuel Sigal, 195318
Assessment of intestinal barrier function in mice with non-alcoholic fatty liver disease subjected to intermittent hypoxia
AASLD LiverLearning®, Marco Arrese, 195574
Dose Dependent Impact of Proton Pump Inhibitors on the Clinical Course of Spontaneous Bacterial Peritonitis
AASLD LiverLearning®, Tammo Tergast, 195319
Synthesis, Biological and Structure-Activity Relationship Evaluation of Bile Acid Derivatives as FXR Agonists for treatment of NASH and PBC
AASLD LiverLearning®, Haiying He, 195575
Trajectory of Serum Creatinine in Liver Transplant Candidates Identifies Patients at High Risk of Mortality
AASLD LiverLearning®, Allison Kwong, 195320
Obesity-Inducing Diet during Conception and Lactation Enhances the Progression of Murine Nonalcoholic Steatohepatitis in Offspring
AASLD LiverLearning®, Kyoko Tomita, 195576
Albumin treatment is Associated with Hyponatremia Correction in Large Multi-center Cirrhotic Inpatient Cohort
AASLD LiverLearning®, Jasmohan Bajaj, 195321